CIK 0001054102 · Non-accelerated filer<br>Smaller reporting company
INTERPACE BIOSCIENCES, INC.
Sign in to watch- Ticker
- IDXG
- Exchange
- OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 222919486
- Phone
- 412-224-6100
- Business address
- WATERVIEW PLAZA, SUITE 310, 2001 ROUTE 46, PARSIPPANY, NJ, 07054
- Former names
- Interpace Diagnostics Group, Inc., PDI INC, PROFESSIONAL DETAILING INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-20 | Burnell Thomas W. CEO, President & Chairman | Option exercise | +1,966,763 | 2,037,645 | ||
| 2026-08-20 | Burnell Thomas W. CEO, President & Chairman | Shares withheld for taxes | −581,718 | $1.61 | $937K | 1,455,927 |
| 2026-08-20 | Burnell Thomas W. CEO, President & Chairman | Grant or award · Restricted Stock Units | +1,966,763 | 1,966,763 | ||
| 2026-08-20 | Burnell Thomas W. CEO, President & Chairman | Option exercise · Restricted Stock Units | −1,966,763 | 0 | ||
| 2026-08-20 | Burnell Thomas W. CEO, President & Chairman | Grant or award · Stock Option (right to buy) | +554,018 | 554,018 | ||
| 2026-08-20 | AGGARWAL VIJAY Director | Grant or award · Restricted Stock Units | +69,252 | 69,252 | ||
| 2026-08-20 | Rocca Fortunato R. Director | Grant or award · Restricted Stock Units | +69,252 | 69,252 | ||
| 2026-08-20 | KEEGAN JOSEPH D Director | Grant or award · Restricted Stock Units | +69,252 | 69,252 | ||
| 2026-08-20 | SULLIVAN STEPHEN J Director | Grant or award · Restricted Stock Units | +69,252 | 69,252 | ||
| 2026-08-20 | McCarthy Christopher CFO & COO | Option exercise | +277,009 | 323,800 | ||
| 2026-08-20 | McCarthy Christopher CFO & COO | Grant or award · Restricted Stock Units | +554,018 | 554,018 | ||
| 2026-08-20 | McCarthy Christopher CFO & COO | Option exercise · Restricted Stock Units | −277,009 | 277,009 | ||
| 2026-08-20 | McCarthy Christopher CFO & COO | Grant or award · Stock Option (right to buy) | +277,009 | 277,009 | ||
| 2026-01-20 | 1315 Capital II, L.P. 10% owner | Conversion | +9,405,941 | $2.02 | $19.0M | 9,405,941 |
| 2026-01-20 | 1315 Capital II, L.P. 10% owner | Conversion · Series C Convertible Preferred Stock | −19,000 | 0 | ||
| 2026-01-20 | Ampersand 2018 Limited Partnership 10% owner | Conversion | +13,861,386 | $2.02 | $28.0M | 13,861,386 |
| 2026-01-20 | Ampersand 2018 Limited Partnership 10% owner | Conversion · Series C Convertible Preferred Stock | −28,000 | 0 | ||
| 2024-12-01 | McCarthy Christopher Chief Financial Officer | Option exercise | +1,111 | 46,791 | ||
| 2024-10-11 | 1315 Capital II, L.P. 10% owner | Returned to the company · Series B Convertible Preferred Stock | +19,000 | 0 | ||
| 2024-10-11 | 1315 Capital II, L.P. 10% owner | Grant or award · Series C Convertible Preferred Stock | +19,000 | 19,000 |
Page 1 of 8 · 158 trades